image: The only peer-reviewed journal covering all trans-disciplinary OMICs-related areas, including data standards and sharing; applications for personalized medicine and public health practice; and social, legal, and ethics analysis. view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, March 2, 2020--A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020. Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon scanning is featured in OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the OMICS: A Journal of Integrative Biology website until April 2, 2020.
Ramy Aziz and Marwa ElRakaiby, Cairo University (Egypt), Mariam Rizkallah, Leibniz Institute for Prevention Research and Epidemiology (Bremen, Germany), and Rama Saad, University of Illinois (Chicago) coauthored the article entitled "Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020." The authors ask the question, "Has the time not come for routine microbiome testing and establishing pharmacomicrobiomic guidelines, at least for some drugs, in 2020?"
The Commentary describes three actionable challenges to translate pharmacomicrobiomics from laboratory bench to patient bedside and personalized medicine innovation: (1) systematic high-throughput microbiome screening studies; (2) phage-enabled precision microbiome engineering/editing; and (3) pharmamicrobiomic testing in the clinic.
Vural Özdemir, MD, PhD, Editor-in-Chief of OMICS: A Journal of Integrative Biology states: "Clinical pharmacomicrobiomics is an exciting and overdue health care innovation field, especially for pharmaceuticals with well-documented drug-microbiome interactions. Pharmacomicrobiomics has come a long way since its debut in 2010. Over the next decade, a growing number of microbiome diagnostics will likely be utilized to choose the right drug, at the right dose, for the right patient, toward personalized medicine. Pharmacomicrobiomics can include both interventional (e.g., microbiome editing) and diagnostic approaches (microbiome testing) for personalized/precision medicine. Authored by pioneers of pharmacomicrobiomics, the new OMICS horizon scanning article offers new insights on the road ahead for microbiome diagnostics in the clinic."
###
About the Journal
OMICS: A Journal of Integrative Biology is an authoritative and highly innovative peer-reviewed interdisciplinary journal published monthly online, addressing the latest advances at the intersection of postgenomics medicine, biotechnology and global society, including the integration of multi-omics knowledge, data analyses and modeling, and applications of high-throughput approaches to study complex biological and societal problems. Public policy, governance and societal aspects of the large-scale biology and 21st century data-enabled sciences are also peer-reviewed. Complete tables of content and a sample issue may be viewed on the OMICS: A Journal of Integrative Biology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Journal of Computational Biology, ASSAY and Drug Development Technologies, and Zebrafish. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.